[1] Karanth H, et, al. pH-sensitive liposomes--principle and application in cancer therapy. J Pharm Pharmacol. 2007 Apr;59(4):469-83. DOI:
10.1211/jpp.59.4.0001[2] Chen L, et, al. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines. AAPS PharmSciTech. 2019 Feb 4;20(3):99. DOI:
10.1208/s12249-019-1316-0[3] KENNETH W.C. MOK Pieter R C Angela M I Lam. Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties[J]. Biochimica et biophysica acta. Biomembranes, 1999, 1419 2: Pages 137-150. DOI:
10.1016/s0005-2736(99)00059-0[4] E G SARAVOLAC. Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity.[J]. Journal of Drug Targeting, 2000, 7 6: 423-437. DOI:
10.3109/10611860009102217[5] ANNA LECHANTEUR*. Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment[J]. Molecular Pharmaceutics, 2017, 14 5: 1706-1717. DOI:
10.1021/acs.molpharmaceut.6b01154
